Compare TECK & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TECK | ZTS |
|---|---|---|
| Founded | 1913 | 1952 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.4B | 32.5B |
| IPO Year | 1997 | 2012 |
| Metric | TECK | ZTS |
|---|---|---|
| Price | $65.25 | $72.62 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 12 |
| Target Price | $53.17 | ★ $154.18 |
| AVG Volume (30 Days) | 2.7M | ★ 3.4M |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | 0.65% | ★ 1.86% |
| EPS Growth | N/A | ★ 10.05 |
| EPS | N/A | ★ 3.08 |
| Revenue | N/A | ★ $9,467,000,000.00 |
| Revenue This Year | $12.43 | $5.63 |
| Revenue Next Year | $4.02 | $4.77 |
| P/E Ratio | $32.94 | ★ $23.71 |
| Revenue Growth | N/A | ★ 2.28 |
| 52 Week Low | $38.00 | $71.00 |
| 52 Week High | $72.56 | $148.79 |
| Indicator | TECK | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 46.37 | 40.63 |
| Support Level | $55.27 | $71.32 |
| Resistance Level | $68.08 | $78.20 |
| Average True Range (ATR) | 1.88 | 1.50 |
| MACD | -0.72 | -0.26 |
| Stochastic Oscillator | 22.38 | 17.23 |
Teck is a base metals miner with copper and zinc operations in Canada, the United States, Chile, and Peru. After selling its metallurgical coal business, copper is now its major commodity by EBITDA contribution, followed by zinc. Teck is a top-three zinc miner. Its major new copper mine in Chile at the majority-owned Quebrada Blanca 2, in partnership with Sumitomo, will drive an increase in Teck's attributable copper production by roughly 80%. Along with a number of additional copper growth options, Teck's strategy is to rebalance its portfolio to low-carbon metals such as copper. It sold its oil sands business in early 2023 and its coal business in mid-2024. In September 2025, it agreed to merge with Anglo American in an all-equity deal.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.